High Penetrances of BRCA1 and BRCA2 Mutations Confirmed in a Prospective Series

Overview

Journal Hered Cancer Clin Pract

Publisher Biomed Central

Specialty Oncology

Date 2010 Feb 26

PMID 20180971

Citations 4

Authors

Pal Moller

Lovise Maehle

Lars F Engebretsen

Trond Ludvigsen

Christoffer Jonsrud

Jaran Apold

Anita Vabo

Neal Clark

Affiliations

Soon will be listed here.

Abstract

Penetrances of BRCA1 and BRCA2 mutations have been derived from retrospective studies, implying the possibility of ascertainment biases to influence the results.We have followed women at risk for breast and/or ovarian cancer for two decades, and report the prospectively observed age-related annual incidence rates to contract breast or ovarian cancer for women with deleterious BRCA1 or BRCA2 mutations based on 4830 observation years. Patients were grouped according to mutation, age and having/not having had previous cancer.In women not having had previous cancer and aged 40-59 years, the annual incidence rate to contract breast or ovarian cancer in those having the most frequent BRCA1 founder mutations was 4.0%, for women in this age group and with less frequent BRCA1 mutations annual incidence rate was 5.9%, and for women with BRCA2 mutations 3.5%.The observed figures may be used for genetic counseling of healthy mutation carriers in the respective age groups. The results may indicate that less frequent BRCA1 mutations have higher penetrances than BRCA1 founder mutations.

Citing Articles

The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway.

Asphaug L, Melberg H MDM Policy Pract. 2019; 4(1):2381468318821103.

PMID: 30746499 PMC: 6360477. DOI: 10.1177/2381468318821103.

Causes for Frequent Pathogenic Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift.

Moller P, Dominguez-Valentin M, Rodland E, Hovig E Cancers (Basel). 2019; 11(2).

PMID: 30678073 PMC: 6406718. DOI: 10.3390/cancers11020132.

mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway.

Heramb C, Wangensteen T, Grindedal E, Ariansen S, Lothe S, Heimdal K Hered Cancer Clin Pract. 2018; 16:3.

PMID: 29339979 PMC: 5761139. DOI: 10.1186/s13053-017-0085-6.

Our genes, our selves: hereditary breast cancer and biological citizenship in Norway.

Solbraekke K, Soiland H, Lode K, Gripsrud B Med Health Care Philos. 2016; 20(1):89-103.

PMID: 27709396 DOI: 10.1007/s11019-016-9737-y.

References

Hagen A, Kvistad K, Maehle L, Holmen M, Aase H, Styr B . Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast. 2007; 16(4):367-74. DOI: 10.1016/j.breast.2007.01.006. View

Easton D, Ford D, Bishop D . Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995; 56(1):265-71. PMC: 1801337. View

Evans D, Baildam A, Anderson E, Brain A, Shenton A, Vasen H . Risk reducing mastectomy: outcomes in 10 European centres. J Med Genet. 2008; 46(4):254-8. DOI: 10.1136/jmg.2008.062232. View

Dorum A, Heimdal K, Hovig E, Inganas M, Moller P . Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer. Am J Hum Genet. 1999; 65(3):671-9. PMC: 1377973. DOI: 10.1086/302530. View

Heimdal K, Maehle L, Apold J, Pedersen J, Moller P . The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. Eur J Cancer. 2003; 39(15):2205-13. DOI: 10.1016/s0959-8049(03)00548-3. View

Moller P, Hagen A, Apold J, Maehle L, Clark N, Fiane B . Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriers. Eur J Cancer. 2007; 43(11):1713-7. DOI: 10.1016/j.ejca.2007.04.023. View

Meijers-Heijboer H, van Geel B, van Putten W, Henzen-Logmans S, Seynaeve C, BARTELS C . Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001; 345(3):159-64. DOI: 10.1056/NEJM200107193450301. View

Evans D, Lennard F, Pointon L, Ramus S, Gayther S, Sodha N . Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study. Cancer Epidemiol Biomarkers Prev. 2009; 18(7):2123-31. PMC: 2869031. DOI: 10.1158/1055-9965.EPI-09-0138. View

Evans D, Shenton A, Woodward E, Lalloo F, Howell A, Maher E . Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer. 2008; 8:155. PMC: 2447846. DOI: 10.1186/1471-2407-8-155. View

10.

Moller P, Evans D, Reis M, Gregory H, Anderson E, Maehle L . Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer. 2007; 121(5):1017-20. DOI: 10.1002/ijc.22789. View

11.

Gorski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E . A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer. 2004; 110(5):683-6. DOI: 10.1002/ijc.20162. View

12.

Antoniou A, Spurdle A, Sinilnikova O, Healey S, Pooley K, Schmutzler R . Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008; 82(4):937-48. PMC: 2427217. DOI: 10.1016/j.ajhg.2008.02.008. View

13.

Bodd T, Reichelt J, Heimdal K, Moller P . Uptake of BRCA1 genetic testing in adult sisters and daughters of known mutation carriers in Norway. J Genet Couns. 2004; 12(5):405-17. DOI: 10.1023/a:1025864703405. View

14.

Begg C, Haile R, Borg A, Malone K, Concannon P, Thomas D . Variation of breast cancer risk among BRCA1/2 carriers. JAMA. 2008; 299(2):194-201. PMC: 2714486. DOI: 10.1001/jama.2007.55-a. View

15.

Evans D, Gaarenstroom K, Stirling D, Shenton A, Maehle L, Dorum A . Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet. 2008; 46(9):593-7. DOI: 10.1136/jmg.2008.058248. View

16.

Einbeigi Z, Bergman A, Kindblom L, Martinsson T, Meis-Kindblom J, Nordling M . A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. Eur J Cancer. 2001; 37(15):1904-9. DOI: 10.1016/s0959-8049(01)00223-4. View

17.

King M, Marks J, Mandell J . Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003; 302(5645):643-6. DOI: 10.1126/science.1088759. View

18.

Maehle L, Apold J, Paulsen T, Hagen B, Lovslett K, Fiane B . High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers. Clin Cancer Res. 2008; 14(22):7569-73. DOI: 10.1158/1078-0432.CCR-08-0112. View

19.

Antoniou A, Pharoah P, Narod S, Risch H, Eyfjord J, Hopper J . Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72(5):1117-30. PMC: 1180265. DOI: 10.1086/375033. View

20.

Moller P, Evans G, Haites N, Vasen H, Reis M, Anderson E . Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. Dis Markers. 1999; 15(1-3):207-11. PMC: 3850824. DOI: 10.1155/1999/920109. View